Meeting
2019 Gastrointestinal Cancers Symposium
Dose intensity of nab-paclitaxel and gemcitabine chemotherapy in metastatic pancreatic cancer.
Authors
Alexander Lim
University of South Florida, Department of Internal Medicine, Tampa, FL
Alexander Lim , Dae Won Kim , Kunhwa Kim , Richard D. Kim , Salvatore Michael Bottiglieri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 251)
DOI
10.1200/JCO.2019.37.4_suppl.251
Abstract #
251
Poster Bd #
D9
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Randomized multicenter phase II/III study of gemcitabine plus nab-paclitaxel or modified FOLFIRINOX or S-IROX in patients with metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE).
First Author: Akihiro Ohba
Poster
2018 Gastrointestinal Cancers Symposium
Efficacy of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX as first line chemotherapy for metastatic pancreatic cancer (mPC): Real world experiences.
First Author: Inhwang Hwang
Poster
2017 Gastrointestinal Cancers Symposium
Clinical outcome of modified FOLFIRINOX versus Gemcitabine plus nab-paclitaxel as first line chemotherapy in metastatic pancreatic cancer.
First Author: Kazuo Watanabe
Poster
2023 ASCO Annual Meeting
CheMo4METPANC: A phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment-naïve pancreas adenocarcinoma.
First Author: Gulam Abbas Manji